ClinicalTrials.gg
CompletedNCT06327009Updated Oct 21, 2026

Effect of Ramadan Fasting on Kidney Function and Proteinuria in Patients With Glomerulonephritis

An observational study in Fasting Ramadan, sponsored by Alexandria University. Completed at 1 site in Egypt. Open to participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by Alexandria University · Observational

How we know

Updated Oct 21, 2026Enrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
128
Ages
18 Months and older
Sex
All
01

Study summary

This research aims to assess effects of ramadan fasting on kidney function and proteinuria in patients with glomerulonephritis.

Read the detailed description

Fasting from sunrise to sunset during the Islamic holy month of Ramadan is one of the five pillars of the Islamic faith. Duration of the fasting ranges from 10 to 18 hours per day according to the geographic location and the season. Although people with chronic illnesses are exempted from fasting according to Islamic beliefs, many patients insist on fasting against medical advice. Through the last three decades many reports studied the potential risks and benefits of fasting Ramadan in regular hemodialysis (HD) patients. Target points of investigation were different. Most of them were focusing on the electrolytes and nutritional changes. Fewer reports tested the mortality rate. In a multicenter observational study, 2055 Egyptian patients from 25 HD units were studied for frequency of fasting in Ramadan and the possible effect of fasting on clinical and biochemical variables. The investigators concluded that nearly 47% of the study patients fasted at least few days of Ramadan. They recommended that HD patients should be encouraged to discuss the option of fasting in Ramadan with their HD staff who might be able to give advice on whether to allow them to fast in days off dialysis with special precautions regarding associated comorbidities, especially diabetes and coronary artery disease. Most of the studies focused on the effects of fasting the month of Ramadan in CKD and hemodialysis patients, but no research assessed these effects specifically in patients with glomerulonephritis.

02

Conditions studied

  • Fasting Ramadan

Browse trials for

Keywords

  • fasting ramadan
  • glomerulonephritis
  • kidney functions
03

In context

Glomerulonephritis

115 studies on the registry are indexed under Glomerulonephritis; 32 are open to participants now.

This study's enrollment of 128 is above the median of 100 across 27 observational studies indexed under Glomerulonephritis.

Browse Glomerulonephritis studies →

Lead sponsor

Alexandria University is the lead sponsor of 610 studies on the registry; 143 are open to participants now.

Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

one hundred patients with biopsy proven glomerulonephritis for more than 3 months from different centers in Egypt will be enrolled in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven glomerulonephritis with ≥ 30 ml/min for more than 3 months (exception is nephrotic patients with positive anti-PLA2R indicative of primary membranous).

Exclusion criteria

Exclusion Criteria:

  • Patients with medical for fasting.
  • Patients with \< 30 ml/min.
  • Patients with acute cardiovascular disease.
  • uncontrolled diabetes mellitus.
  • active or chronic inflammatory disease.
  • Acute liver disease.
  • Pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
128 participants (actual)
Patient registry
No

Groups and cohorts

  • fasting

    128 patients who decided to fast the month of ramadan.

    Behavioral: fasting month of ramadan

Interventions

  • Behavioralfasting month of ramadan

    128 patients with glomerulonephritis who decided to fast month of ramadan

06

What researchers measure

Primary outcomes

  1. Change in kidney function

    By assessing change in eGFR

    Time frame: 4 weeks (month of ramadan)

  2. Change in proteinuria

    By assessing change in protein to creatinine ratio in urine

    Time frame: 4 weeks (month of ramadan)

07

Study locations

1 site
  • Faculty of Medicine, Aexandria University
    Alexandria, 21526, Egypt
08

References and documents

Publications

  • Sahin SB, Ayaz T, Ozyurt N, Ilkkilic K, Kirvar A, Sezgin H. The impact of fasting during Ramadan on the glycemic control of patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2013 Oct;121(9):531-4. doi: 10.1055/s-0033-1347247. Epub 2013 Aug 9. PubMed 23934679 ↗
  • Megahed AF, El-Kannishy G, Sayed-Ahmed N. Status of fasting in Ramadan of chronic hemodialysis patients all over Egypt: A multicenter observational study. Saudi J Kidney Dis Transpl. 2019 Mar-Apr;30(2):339-349. doi: 10.4103/1319-2442.256841. PubMed 31031370 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2024 to primary completion in Apr 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 25, 2024
StartActual
Mar 22, 2024
Primary completionActual
Apr 22, 2024
CompletionActual
Jun 14, 2024
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
100→128
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Enrollment 100→128
    + 4 other changes: index terms, verification date, arm descriptions and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06327009
Responsible party
Mohamed Mamdouh Mahmoud Mohamed Elsayed , MD (assistant professor, Alexandria University) — Principal investigator
First posted
Mar 25, 2024
Start date
Mar 22, 2024
Primary completion
Apr 22, 2024
Completion
Jun 14, 2024
Last update
Oct 21, 2026

Study contacts

Mohamed Mamdouh Elsayed, MD
principal investigator · assistant professor
kariem M salem, MD
study chair · lecturer

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion